


## Operating Procedures



- The global leading on-site nucleic acid testing device
- Concluding test results 2 days earlier than antigen tests
- Comprehensive application, expandable for multi-variants detection



Website



Video



LinkedIn



Line

### Guangzhou Pluslife Biotech Co.,Ltd

Floor 3, Block E, Runhui Science & Technology Park, No. 18 Shenzhou RD, Huangpu District, Guangzhou, Guangdong, China

market@pluslife.com

www.pluslife.com

+86-20-31703986

PLCOV-INT-20230322

## Mini Dock

COVID-19  
Nucleic Acid Testing System

98.91% Sensitivity, 99.58% Specificity





## Clinically Proven

In individual clinical studies of personnel who have COVID-19 symptoms and asymptomatic infected, Pluslife Mini Dock achieved an accurate detection rate that comparable to qPCR nucleic acid detection, presenting exceptional sensitivity and specificity.

### Data of the Comparative Clinical Studies

Pluslife	RT-PCR		Total
	Positive	Negative	
Positive	true positive (TP) 181	false positive (FP) 0	TP+FP 181
Negative	false negative (FN) 2	true negative (TN) 70	FN+TN 72
Total	TP+FN 183	FP+TN 70	253


**98.91% Sensitivity, 99.58% Specificity**

According to the clinical comparative study performed in IlexLab, the Institute of Clinical Research in Israel on February, the molecular detection system from Pluslife achieves identical results comparing to RT-PCR.

## Comparison between Pluslife and Antigen Tests

Pluslife Mini Dock has consistent capacity for detecting targets with 400 copies/ml of SARS-CoV-2 virus, achieving much higher sensitivity than the antigen tests. According to the load of the virus in the body, the virus can be detected nearly 2 days in advance comparing to antigen tests and the infection can be detected in time to prevent further outbreak.

Testing Method	Manufacturer	Performances
Nucleic Acid Test	Pluslife	Effectively detect sample with Ct-value reached 44.8
Antigen Test	122 Products from different producers	85% of the products miss all the sample with Ct >30 (Scheiblaue H, 2021)




Killingley B, 2022

## Pluslife Mini Dock PM001

Pluslife Mini Dock is a rapid molecular detection system for detecting infectious diseases included COVID-19. Based on the self-developed isothermal molecular detection technology, the Mini Dock is able to provide accurate test results that are comparable to top laboratory PCR tests, while it is easier to use and move around and only takes 15 to 35 mins to conclude the result.

## Method: RHAM

The assay is based on RHAM, a self-developed isothermal amplification molecular detection technology. The RHAM system includes two reactions of isothermal amplification and signal release. The two reactions can be carried out simultaneously without the need for steps to speedup the reaction time. The isothermal amplification adopts optimized high-performance enzymes to obtain ultra-sensitive detection results. Signal release introduces ingenious specificity-enhancing steps that fundamentally prevent false positives from occurring. Overall, the performance of RHAM is comparable to that of qPCR, and far superior to conventional isothermal amplification (such as LAMP, etc.) techniques.



### Advantages of molecular testing over antigen testing:

Antigen detection can only detect the original concentration of the virus surface protein molecules in the respiratory tract. If the target is in the early stage of infection or asymptomatic infection, it is likely to be missed due to low virus content, but these infected are still quite infectious to others.

Molecular testing can amplify viral RNA millions of times and it could detect extra low levels of virus in the body, so the results are more accurate and reliable.